[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,70,99,123,147,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100645202","ai-technologies-for-enhanced-and-celerated-high-field-wb-mri-100645202",false,"NCT07678320","AI Technologies for Enhanced and Celerated High-Field WB-MRI","AITECH-MRI","Inclusion Criteria:\n\n* Consecutive adults (≥18 y.o.) admitted to the UO for W MRI for screening procedure.\n* Consecutive adult male patients (≥18 y.o.) admitted to the UO for WB-MRI for screening procedure and focus on prostate.\n\nExclusion Criteria:\n\n* refused to consent\n* claustrophobia\n* metal prosthesis potentially affecting image quality",true,"ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","Single-center, cross-sectional observational study assessing the feasibility of advanced accelerated MRI sequences versus standard ones in terms of image quality, diagnostic reliability, and acquisition time.",[25,26,27,28,29],"Whole Body Imaging","Prostate","MRI","Lung","Vascular",[27,31,32,33,29],"Whole Body","Accelerated Imaging","Prostate Imaging","NOT_YET_RECRUITING","2026-06-25",{"date":37,"type":38},"2026-07-01","ACTUAL",{"date":37,"type":21},{"date":41,"type":21},"2029-05-01",{"name":43,"class":44},"IRCCS San Raffaele","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100639094","phase-2-low-dose-thoracic-radiotherapy-followed-by-adebrelimab-plus-chemotherapy-and-then-sequential-maintenance-therapy-with-adebrelimab-for-extensive-stage-small-cell-lung-cancer-100639094","NCT07583550","Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer","Efficacy and Safety of Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy and Sequential Adebrelimab Maintenance Therapy for Extensive-stage Small Cell Lung Cancer: A Prospective, Multicenter Phase II Study","Inclusion Criteria:\n\n1. Age ≥18 years and ≤75 years.\n2. Histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC).\n3. No prior systemic anti-tumor therapy.\n4. ECOG performance status 0-2 and life expectancy ≥12 weeks.\n5. At least one measurable lesion per RECIST version 1.1.\n6. No brainstem metastasis and no significant neurological symptoms from brain metastases.\n7. All participants must undergo routine contrast-enhanced CT of the chest and upper abdomen, as well as brain MRI, before enrollment. Whole-body PET-CT plus brain MRI is preferred. For participants with limited financial resources who also have significant obstructive pneumonia or atelectasis, an additional chest MRI is recommended.\n8. No malignant pleural effusion or pericardial effusion.\n9. All participants must provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of interstitial pneumonia or infectious fever prior to treatment.\n2. Comorbid autoimmune diseases or long-term oral corticosteroid use (including those who received oral corticosteroids within 14 days prior to treatment).\n3. Prior history of thoracic radiotherapy or thoracic surgery.\n4. Presence of Grade ≥3 hematologic toxicity or hepatic\u002Frenal impairment.\n5. Hypersensitivity to adebrelimab.\n6. Significant respiratory symptoms that preclude tolerance to radiotherapy.\n7. Active hepatitis B or hepatitis C infection with ongoing antiviral therapy. Subjects with a documented history of HBV infection who have achieved undetectable HBV levels after prior active treatment at the time of enrollment may be included.\n8. Presence of pleural effusion or pericardial effusion.","75 Years",{"count":54,"type":21},43,"INTERVENTIONAL",[57],"PHASE2","This multicenter, prospective study aims to investigate the efficacy and safety of low-dose radiotherapy (15Gy\u002F1.5 Gy bid × 10 fractions) combined with 4-6 cycles of systemic chemotherapy plus anti-PD-L1 antibody, followed by anti-PD-L1 antibody maintenance for up to two years, in participants with extensive-stage small cell lung cancer (ES-SCLC).\n\nAdditionally, dynamic monitoring using next-generation sequencing (NGS) technology will be performed to assess ctDNA levels, genetic information, and mutation abundance at the following time points: before and after low-dose radiotherapy, after 4-6 cycles of chemotherapy plus anti-PD-L1 antibody (chemotherapy-immunotherapy), and before the initiation of anti-PD-L1 maintenance therapy. This approach aims to guide efficacy and prognosis prediction, as well as to identify potential biomarkers associated with treatment response.",[28,60],"Radiotherapy","2026-05-06",{"date":63,"type":38},"2026-05-13",{"date":65,"type":21},"2026-05-01",{"date":67,"type":21},"2028-01-01",{"name":69,"class":44},"Jiangmen Central Hospital",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":55,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100524950","non-invasive-ventilation-assisted-fiber-optic-bronchoscopy-100524950","NCT06115395","Non-invasive Ventilation Assisted Fiber-optic Bronchoscopy","Efficacy and Safety of Using Non-invasive Ventilation Assisted Fiber-optic Bronchoscopy","Inclusion Criteria:\n\n* Patients who admitted to the pulmonology ward or intensive care unit with any (diagnostic and\u002For therapeutic) bronchoscopy indication.\n\n  1. Age 18 years or more.\n  2. Patients accepted to participate in the study.\n\nExclusion Criteria:\n\n* Patients with:\n\n  1. Cardiac or respiratory arrest.\n  2. Impaired consciousness or confusion.\n  3. Type II respiratory failure.\n  4. Hemodynamic instability.\n  5. Inability to cooperate or to protect the airway.\n  6. Vomiting, bowel obstruction, recent upper gastrointestinal tract surgery and esophageal injury.\n  7. Patients refusing participation in the study.\n  8. Patients unfit for NIV and or NIV mask.\n  9. Intubation and or invasive ventilation candidates.\n  10. Presence of contraindications for bronchoscopy procedure such as insufficient platelet number or coagulopathy.","70 Years",{"count":79,"type":21},100,[81],"NA","The purpose of this study is the evaluation of using bi-level positive airway pressure ventilation in candidates for fiber-optic bronchoscopy regarding benefits and drawbacks.",[28,84],"Diseases",[86,87],"non- invasive ventilation","fiber-optic bronchoscopy.","RECRUITING","2025-05-07",{"date":91,"type":38},"2025-05-11",{"date":93,"type":38},"2020-07-25",{"date":95,"type":21},"2025-12-31",{"name":97,"class":44},"Mansoura University",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":106,"targetDuration":108,"studyType":22,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":98},"100580930","establishing-a-longitudinal-cohort-study-of-lung-cancer-using-tissue-and-peripheral-blood-metabolomics-100580930","NCT06843707","Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.","Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics to Explore Biomarkers and Therapeutic Mechanisms.","Inclusion Criteria:\n\n1. Signing of the informed consent form;\n2. Male or female, aged 18-75 years;\n3. Patients with lung nodules confirmed by CT examination;\n4. Good preoperative pulmonary function cooperation and complete reporting;\n5. Preoperative chest single\u002Fdual phase CT scans without significant artefacts and with complete imaging;\n6. The interval between preoperative pulmonary function and single\u002Fdual phase CT scans does not exceed one month.\n\nExclusion Criteria:\n\n1. Poor preoperative pulmonary function cooperation or missing reports;\n2. Preoperative chest single\u002Fdual phase CT scans exhibit significant artefacts or image omission;\n3. The interval between preoperative pulmonary function and single\u002Fdual phase CT scans exceeds one month;\n4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);\n5. Coexisting with other severe functional impairments;\n6. Patients with obstructive lesions such as airway or esophageal stenosis;\n\n(8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.",{"count":107,"type":21},2500,"5 Years","This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of metabolomics in the diagnosis, prognosis, and therapeutic monitoring of lung cancer. By profiling metabolic alterations, this study aims to identify potential biomarkers for distinguishing benign and malignant lung nodules, predicting therapeutic efficacy, and assessing long-term prognosis. Key time points include initial screening for lung nodules, postoperative evaluation to predict treatment outcomes, and therapeutic monitoring to assess efficacy after medication or other interventions. Through these analyses, the study seeks to uncover underlying metabolic mechanisms and provide valuable insights into personalized lung cancer management.",[111,28,112,113],"Lung Cancer","Lung Cancer (NSCLC)","Metabolomics","2025-02-24",{"date":116,"type":38},"2025-02-25",{"date":118,"type":38},"2024-01-01",{"date":120,"type":21},"2027-12-31",{"name":122,"class":44},"The First Affiliated Hospital of Guangzhou Medical University",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100578738","pulsed-eco-doppler-for-polmonal-discharge-velocity-100578738","NCT06815198","Pulsed Eco Doppler for Polmonal Discharge Velocity","Pulsed Eco Doppler for the Study of Polmonal Discharge Velocity: Pilot\u002FExplorative Study","VeLung","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Acquisition of Informed Consent\n\nExclusion Criteria:\n\n* Patients admitted to undergo major thoracic surgery.\n* Remote pathological history positive for recurrent PNX (≥ 2), pleural thalking or pleurodesis\n* Patients presenting with absolute and relative contraindications to spirometry for1 and 2a patients ie:\n\nrecent myocardial infarction (within the past 3 months) or unstable angina hemoptysis thoracic aortic aneurysm",{"count":79,"type":21},"Chest ultrasound is increasingly being used in the diagnosis and management of the respiratory patient. With ultrasound, ultrasound artifacts representing the lung during inspiration and during exhalation are visualized and analyzed. During inspiration, the lung inflates with air while when exhaling, the lung empties. These two phases are visualized on ultrasound with a sliding motion of the pleural line, which represents the margin of the lung.\n\nThe aim of the study is to identify the speed of filling and emptying of the lung by studying the characteristics of the pulsed Doppler wave to measure the speed of lung sliding as the significance of this finding has not yet been clarified. In both healthy subjects and patients with lung disease, it is not known whether there is a correlation between velocity measured by the Doppler wave with the main data recorded by a mechanical ventilator or spirometer.",[134],"LUNG",[136],"PULSED ECO DOPPLER, LUNG","2025-02-03",{"date":139,"type":38},"2025-02-07",{"date":141,"type":38},"2021-05-06",{"date":143,"type":21},"2025-06-30",{"name":145,"class":44},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",2,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":153,"targetDuration":108,"studyType":22,"phases":4,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":98},"100575917","lcprot-proteomics-longitudinal-cohort-study-on-lung-cancer-100575917","NCT06778512","LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer","LcProt: Proteomics Longitudinal Cohort Study on Lung CancerProspective Longitudinal Cohort Study of Lung Cancer Based on Peripheral Blood and Tissue Proteomics",{"count":107,"type":21},"This study will utilize tissue and peripheral blood samples for proteomics analysis and establish a longitudinal proteomics cohort at multiple critical treatment time points to explore the research value of proteomics in the diagnosis and treatment of lung cancer. The study includes key time points such as screening, postoperative efficacy prediction, and efficacy prediction after medication.",[28,111,156,157],"Cancer","NSCLC",[159,160,161,157],"Lung cancer","Proteomics","Protein","2025-01-12",{"date":164,"type":38},"2025-01-16",{"date":166,"type":38},"2019-06-01",{"date":168,"type":21},"2026-12",{"name":122,"class":44},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":55,"phases":179,"briefSummary":181,"conditions":182,"keywords":191,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":98},"100562399","phase-1-reinforced-and-non-reinforced-staple-lines-in-fissureless-lobectomy-100562399","NCT06602661","Reinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy","A Prospective Randomized Study of Reinforced Vs Non-reinforced Staple Lines in Fissureless Lobectomy","Inclusion Criteria:\n\n* Patients aged 18 and over.\n* Patients undergoing fissureless lobectomy for lung carcinoma.\n\nExclusion Criteria:\n\n* Patients suitable for sub lobar resections.\n* Patients undergoing lobectomy for indications other than lung cancer.\n* Patients with a history of pleural adhesions.\n* Patients with previous lung resection on the same side.",{"count":178,"type":21},65,[180],"PHASE1","Prolonged Air Leak (PAL) is a common and serious problem after lung surgery. It can lead to worse patient outcomes, longer hospital stays, and higher costs. Reinforced staplers are designed to make the staple line stronger and reduce the risk of PAL. However, investigators don't know if they are better than standard staplers, especially in a specific type of lung surgery called fissureless lobectomy for lung cancer. This study aims to find out if reinforced staplers are more effective at reducing PAL and its complications compared to non-reinforced staplers.\n\nReinforced staplers have been used in lung surgeries and have shown to reduce PAL. For example, staplers with special materials like polyglycolic acid (PGA) sheets have shown lower air leakage and fewer days with chest tubes. Other materials like expanded polytetrafluoroethylene (ePTFE) sleeves have also been used to manage air leaks in different types of lung surgeries. However, their effectiveness in fissureless lobectomy has not been studied yet.",[28,183,184,185,186,187,188,189,190],"Lung Adenocarcinoma","Lung Adenosquamous Carcinoma","Lung Cancer, Non-Small Cell","Lung Carcinoma","Lobectomy","Lobectomy Patient","Lobectomy by Video-thoracoscopies","VATS",[192,193,194,195,196,186,197,198,199,200,201,202,203,204,205,206,207,208,209,210],"Prospective Randomized Study","Fissureless Lobectomy","Prolonged Air Leak (PAL)","Pulmonary Resections","Hospital Length of Stay (LOS)","Echelon 3000 stapler","Endopath Stapler Line Reinforcement","Video-Assisted Thoracoscopic Surgery (VATS)","Postoperative Outcomes","Intraoperative Characteristics","Randomized Control Trial (RCT)","Surrey Memorial Hospital (SMH)","Surrey Thoracic Surgery Group (STSG)","Digital Drainage System (Thopaz)","Chest Tube Duration","Hospital Readmission","Patient Outcomes","Bioabsorbable Buttress Material","Polyglactin and Polydioxanone","2024-09-17",{"date":213,"type":38},"2024-09-19",{"date":215,"type":21},"2025-01-01",{"date":217,"type":21},"2028-01",{"name":219,"class":44},"Surrey Thoracic Surgery Group"]